Veloxis is expecting an operating loss of DKK 200 - 240 million compared to the realized operating loss of DKK 59 million in 2014.
Net loss is expected to be in the range of DKK 195 - 235 million compared to the net loss of DKK 36 million in 2014.
As of 31 December 2014, the Company’s cash position equaled DKK 270 million and the Company’s 31 December 2015 cash position is expected to be in the range of DKK 55 - 95 million.
The above estimates are assuming launch of Envarsus® XR in the US in the second half of 2015. The outlook is therefore subject to possible changes primarily related to the timing and outcome of the ongoing lawsuit regarding approval of Envarsus® XR.
Management is focused on securing additional funds beyond 2015 by either partner agreements, debt or equity, or a mix thereof.